OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ALEMS54

European Medical Solutions SA

Healthcare Facilities & ServicesVerified

European Medical Solutions SA has a basic share count of 4,231,839 and a diluted share count of 4,231,839, indicating no dilution from potential equity instruments. The company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company reported revenue of EUR 9,400,000, but no profitability metrics or returns data are available for comparison against industry benchmarks. Without detailed financial metrics, it is not possible to assess the company's performance relative to its peers. There is no information provided on the company's business segments or geographic exposure, making it difficult to evaluate revenue concentration or diversification. The company's growth trajectory cannot be determined due to the lack of historical revenue data and forward-looking guidance. No specific growth drivers or challenges are identified in the available data. The risk assessment indicates a low dilution potential, but liquidity risk could not be evaluated due to missing balance-sheet data. No adjustments were applied to the valuation metrics due to the lack of necessary inputs. No recent events, such as filings or transcripts, are available to provide insight into the company's current operations or strategic direction.

30-day price · ALEMS-0.52 (-9.6%)
Low$4.70High$5.40Close$4.88As of16 May, 00:00 UTC
Profile
CompanyEuropean Medical Solutions SA
TickerALEMS.BR
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. European Medical Solutions SA operates in the healthcare sector, focusing on pharmaceuticals and healthcare facilities and services.

Classification. The company is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Healthcare Facilities & Services industry with a confidence level of 0.92.

European Medical Solutions SA has a basic share count of 4,231,839 and a diluted share count of 4,231,839, indicating no dilution from potential equity instruments. The company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company reported revenue of EUR 9,400,000, but no profitability metrics or returns data are available for comparison against industry benchmarks. Without detailed financial metrics, it is not possible to assess the company's performance relative to its peers. There is no information provided on the company's business segments or geographic exposure, making it difficult to evaluate revenue concentration or diversification. The company's growth trajectory cannot be determined due to the lack of historical revenue data and forward-looking guidance. No specific growth drivers or challenges are identified in the available data. The risk assessment indicates a low dilution potential, but liquidity risk could not be evaluated due to missing balance-sheet data. No adjustments were applied to the valuation metrics due to the lack of necessary inputs. No recent events, such as filings or transcripts, are available to provide insight into the company's current operations or strategic direction.
Key takeaways
  • European Medical Solutions SA operates in the healthcare sector with a focus on pharmaceuticals and healthcare services.
  • The company has no dilution from potential equity instruments, as basic and diluted share counts are equal.
  • Revenue for the company is reported at EUR 9,400,000, but no profitability or return metrics are available for comparison.
  • The company's liquidity position could not be assessed due to missing balance-sheet data.
  • No information is available on the company's business segments or geographic exposure.
  • Growth trajectory and recent strategic developments cannot be determined from the available data.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$9.4M
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$36.3M$29.0k-$241.0k-$231.0k
FY-3$35.3M-$5.3M-$5.6M-$5.7M
FY-2$42.2M-$2.3M-$4.9M-$10.2M
FY-1$45.1M$1.3M$546.0k-$694.0k
FY0$49.9M$2.5M$1.8M$1.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$36.3M$10.8M$2.4M
FY-3$39.9M$10.6M$4.2M
FY-2$51.1M$12.4M$4.8M
FY-1$48.5M$10.3M$4.6M
FY0$51.8M$12.1M$4.9M
PeriodOCFCapExFCFSBC
FY-4$348.0k-$1.9M-$231.0k
FY-3$2.3M-$2.2M-$5.7M
FY-2-$1.6M-$2.7M-$10.2M
FY-1$2.6M-$3.6M-$694.0k
FY0$5.4M-$2.9M$1.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$9.4M
FQ-6
FQ-5$10.0M
FQ-4
FQ-3$10.9M
FQ-2
FQ-1$11.0M
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricALEMSActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 01:52 UTC#9c559f35
Market quoteclose EUR 5.25 · shares 0.00B diluted
no public URL
2026-05-03 20:28 UTC#11b135c6
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 07:48 UTCJob: 5ea2cef8